Literature DB >> 11465409

Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor.

J V Aukunuru1, G Sunkara, N Bandi, W B Thoreson, U B Kompella.   

Abstract

PURPOSE: The objective of this study was to determine the expression and activity of multidrug resistance-associated protein (MRP) in the retinal pigment epithelial (RPE) cells and to further assess whether BAPSG, a novel anionic aldose reductase inhibitor, interacts with MRP.
METHODS: Functional and biochemical evidence for MRP was obtained in a human retinal pigment epithelial (ARPE-19) cell line and primary cultures of human retinal pigment epithelial (HRPE) cells. Fluorescein accumulation and efflux in the presence and absence of MRP inhibitors was used to obtain functional evidence for MRP. Western blots and RT-PCR were used to obtain biochemical evidence for MRP1. The influence of MRP inhibitors on BAPSG accumulation and efflux in ARPE-19 cells was determined to understand its interaction with MRP.
RESULTS: MRP inhibitors increased fluorescein accumulation and reduced efflux in RPE cells. Both cell types exhibited a 190-kDa western blot band corresponding to MRP1 protein and a 287 bp RT-PCR band corresponding to MRP1 mRNA. MRP inhibitors reduced BAPSG efflux and increased its accumulation in ARPE-19 cells.
CONCLUSIONS: MRP is functionally and biochemically active in human RPE cells. Anionic BAPSG is a likely substrate for MRP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465409     DOI: 10.1023/a:1011060705599

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells.

Authors:  Y Zhang; H Han; W F Elmquist; D W Miller
Journal:  Brain Res       Date:  2000-09-08       Impact factor: 3.252

2.  Lysophosphatidic acid stimulates proliferation of human retinal pigment epithelial cells.

Authors:  W B Thoreson; B N Khandalavala; R G Manahan; I A Polyak; J L Liu; D M Chacko
Journal:  Curr Eye Res       Date:  1997-07       Impact factor: 2.424

3.  Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells.

Authors:  M Kool; M van der Linden; M de Haas; F Baas; P Borst
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.

Authors:  S Gollapudi; C H Kim; B N Tran; S Sangha; S Gupta
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

5.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

Authors:  V V Rao; J L Dahlheimer; M E Bardgett; A Z Snyder; R A Finch; A C Sartorelli; D Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor.

Authors:  G Sunkara; J Deruiter; C R Clark; U B Kompella
Journal:  J Pharm Pharmacol       Date:  2000-09       Impact factor: 3.765

7.  Detection of MRP1 mRNA in human tumors and tumor cell lines by in situ RT-PCR.

Authors:  L Pascolo; C Fernetti; D Pirulli; S Bogoni; M V Garcia-Mediavilla; A Spanò; D Puzzer; C Tiribelli; A Amoroso; S Crovella
Journal:  Biochem Biophys Res Commun       Date:  2000-08-28       Impact factor: 3.575

8.  Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.

Authors:  G L Scheffer; M Kool; M Heijn; M de Haas; A C Pijnenborg; J Wijnholds; A van Helvoort; M C de Jong; J H Hooijberg; C A Mol; M van der Linden; J M de Vree; P van der Valk; R P Elferink; P Borst; R J Scheper
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells.

Authors:  Z Holló; L Homolya; T Hegedüs; B Sarkadi
Journal:  FEBS Lett       Date:  1996-03-25       Impact factor: 4.124

10.  Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.

Authors:  M P Draper; R L Martell; S B Levy
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  23 in total

1.  Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes.

Authors:  Scott M Ocheltree; Richard F Keep; Hong Shen; Dongli Yang; Bret A Hughes; David E Smith
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 2.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

3.  In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.

Authors:  Sai H S Boddu; Jwala Jwala; Monica R Chowdhury; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

4.  The calcium channel mucolipin-3 is a novel regulator of trafficking along the endosomal pathway.

Authors:  Jose A Martina; Benjamin Lelouvier; Rosa Puertollano
Journal:  Traffic       Date:  2009-04-29       Impact factor: 6.215

Review 5.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

6.  Planar microdevices enhance transport of large molecular weight molecules across retinal pigment epithelial cells.

Authors:  Jennifer S Wade; Tejal A Desai
Journal:  Biomed Microdevices       Date:  2014-08       Impact factor: 2.838

7.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

Review 8.  Intraocular sustained-release delivery systems for triamcinolone acetonide.

Authors:  Saffar Mansoor; Baruch D Kuppermann; M Cristina Kenney
Journal:  Pharm Res       Date:  2009-01-28       Impact factor: 4.200

9.  Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.

Authors:  Gangadhar Sunkara; Surya P Ayalasomayajula; Jack DeRuiter; Uday B Kompella
Journal:  Brain Res Bull       Date:  2009-09-15       Impact factor: 4.077

10.  Efflux protein expression in human retinal pigment epithelium cell lines.

Authors:  Eliisa Mannermaa; Kati-Sisko Vellonen; Tuomas Ryhänen; Katriina Kokkonen; Veli-Pekka Ranta; Kai Kaarniranta; Arto Urtti
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.